Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma.
Akos NagyBence BátaiLaura KissStefánia GrófPéter Attila KirályÁdám JónaJudit DemeterHermina SántaÁrpád BátaiPiroska PettendiTamás SzendreiMárk PlanderGábor KörösmezeyHussain AlizadehBéla KajtárGábor MéhesLászló KrenácsBotond TimárJudit CsomorErika TóthTamás SchneiderGábor MikalaAndrás MatolcsyDonát AlpárAndrás MassziCsaba BödörPublished in: Journal of internal medicine (2023)
The in-depth spatio-temporal analysis identified EZH2 mutations in a considerably higher proportion of patients than previously reported. This expands the subset of FL patients who most likely would benefit from EZH2 inhibitor therapy. This article is protected by copyright. All rights reserved.
Keyphrases
- end stage renal disease
- long non coding rna
- newly diagnosed
- chronic kidney disease
- ultrasound guided
- ejection fraction
- long noncoding rna
- peritoneal dialysis
- fine needle aspiration
- prognostic factors
- mesenchymal stem cells
- patient reported outcomes
- stem cells
- optical coherence tomography
- patient reported
- bone marrow
- data analysis